Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort
Background: Hypertensive disorders of pregnancy (HDP), defined here as hypertensive disorders with onset in pregnancy (i.e., gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension), affect up to 10% of pregnancies in the United States and are associated with su...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-07-01
|
| Series: | Environment International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0160412022002628 |
| _version_ | 1818555807701139456 |
|---|---|
| author | Emma V. Preston Marie-France Hivert Abby F. Fleisch Antonia M. Calafat Sharon K. Sagiv Wei Perng Sheryl L. Rifas-Shiman Jorge E. Chavarro Emily Oken Ami R. Zota Tamarra James-Todd |
| author_facet | Emma V. Preston Marie-France Hivert Abby F. Fleisch Antonia M. Calafat Sharon K. Sagiv Wei Perng Sheryl L. Rifas-Shiman Jorge E. Chavarro Emily Oken Ami R. Zota Tamarra James-Todd |
| author_sort | Emma V. Preston |
| collection | DOAJ |
| description | Background: Hypertensive disorders of pregnancy (HDP), defined here as hypertensive disorders with onset in pregnancy (i.e., gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension), affect up to 10% of pregnancies in the United States and are associated with substantial maternal and neonatal morbidity and mortality. Per- and polyfluoroalkyl substances (PFAS) are associated with adverse cardiometabolic outcomes during pregnancy, but associations between PFAS and HDP are inconsistent and joint effects of PFAS mixtures have not been evaluated. Methods: We studied 1,558 pregnant individuals from the Project Viva cohort, recruited during 1999–2002. We quantified concentrations of eight PFAS in plasma samples (median 9.7 weeks of gestation). Using clinical records, we calculated trimester-specific mean systolic (SBP) and diastolic (DBP) blood pressure and categorized HDP status [no HDP (normotensive & chronic hypertension), gestational hypertension, preeclampsia]. We estimated associations of individual PFAS with HDP using multinomial logistic regression and estimated associations with blood pressure using linear regression. We used Bayesian kernel machine regression (BKMR) and quantile g-computation to assess joint effects of the PFAS mixture on HDP and blood pressure measures. Results: Four percent of participants developed preeclampsia and 7% developed gestational hypertension. We observed higher odds of gestational hypertension, but not preeclampsia, per doubling of perfluorooctanoate (PFOA) [OR = 1.51 (95% confidence interval: 1.12, 2.03)], perfluorooctane sulfonate (PFOS) [OR = 1.38 (1.04, 1.82)], and perfluorohexane sulfonate [OR = 1.28 (1.06, 1.54)] concentrations. We observed higher mean DBP per doubling of PFOA [2nd trimester (T2): 0.39 mmHg (−0.01, 0.78); 3rd trimester (T3): 0.56 mmHg (0.14, 0.98)] and PFOS [T2: 0.46 mmHg (0.11, 0.82); T3: 0.43 mmHg (0.05, 0.80)]. The PFAS mixture was positively associated with odds of gestational hypertension [75th vs. 50th percentile: OR = 1.14 (95% credible interval:1.03, 1.25), BKMR] and mean DBP [T2 = 0.17 mmHg (−0.06, 0.40); T3 = 0.22 mmHg (−0.03, 0.48), BKMR]. Conclusions: These findings suggest that exposure to certain PFAS may increase the odds of gestational hypertension during pregnancy, with potential implications for subsequent maternal and child health outcomes. |
| first_indexed | 2024-12-12T09:58:24Z |
| format | Article |
| id | doaj.art-8cc02ee7a88841069ab5a49d8510dd24 |
| institution | Directory Open Access Journal |
| issn | 0160-4120 |
| language | English |
| last_indexed | 2024-12-12T09:58:24Z |
| publishDate | 2022-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Environment International |
| spelling | doaj.art-8cc02ee7a88841069ab5a49d8510dd242022-12-22T00:28:03ZengElsevierEnvironment International0160-41202022-07-01165107335Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohortEmma V. Preston0Marie-France Hivert1Abby F. Fleisch2Antonia M. Calafat3Sharon K. Sagiv4Wei Perng5Sheryl L. Rifas-Shiman6Jorge E. Chavarro7Emily Oken8Ami R. Zota9Tamarra James-Todd10Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Corresponding author at: Department of Environmental Health, Harvard T.H. Chan School of Public Health, 665 Huntington Ave, Building 1, Room 1305, Boston, MA 02115, United States.Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States; Diabetes Unit, Massachusetts General Hospital, Boston, MA, United StatesCenter for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, United States; Pediatric Endocrinology and Diabetes, Maine Medical Center, Portland, ME, United StatesNational Center for Environmental Health, U.S. Centers for Disease Control and Prevention, Atlanta, GA, United StatesCenter for Environmental Research and Children’s Health (CERCH), School of Public Health, University of California at Berkeley, Berkeley, CA, United StatesDepartment of Epidemiology and the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesDivision of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United StatesDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United StatesDivision of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United StatesDepartment of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC, United StatesDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United StatesBackground: Hypertensive disorders of pregnancy (HDP), defined here as hypertensive disorders with onset in pregnancy (i.e., gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension), affect up to 10% of pregnancies in the United States and are associated with substantial maternal and neonatal morbidity and mortality. Per- and polyfluoroalkyl substances (PFAS) are associated with adverse cardiometabolic outcomes during pregnancy, but associations between PFAS and HDP are inconsistent and joint effects of PFAS mixtures have not been evaluated. Methods: We studied 1,558 pregnant individuals from the Project Viva cohort, recruited during 1999–2002. We quantified concentrations of eight PFAS in plasma samples (median 9.7 weeks of gestation). Using clinical records, we calculated trimester-specific mean systolic (SBP) and diastolic (DBP) blood pressure and categorized HDP status [no HDP (normotensive & chronic hypertension), gestational hypertension, preeclampsia]. We estimated associations of individual PFAS with HDP using multinomial logistic regression and estimated associations with blood pressure using linear regression. We used Bayesian kernel machine regression (BKMR) and quantile g-computation to assess joint effects of the PFAS mixture on HDP and blood pressure measures. Results: Four percent of participants developed preeclampsia and 7% developed gestational hypertension. We observed higher odds of gestational hypertension, but not preeclampsia, per doubling of perfluorooctanoate (PFOA) [OR = 1.51 (95% confidence interval: 1.12, 2.03)], perfluorooctane sulfonate (PFOS) [OR = 1.38 (1.04, 1.82)], and perfluorohexane sulfonate [OR = 1.28 (1.06, 1.54)] concentrations. We observed higher mean DBP per doubling of PFOA [2nd trimester (T2): 0.39 mmHg (−0.01, 0.78); 3rd trimester (T3): 0.56 mmHg (0.14, 0.98)] and PFOS [T2: 0.46 mmHg (0.11, 0.82); T3: 0.43 mmHg (0.05, 0.80)]. The PFAS mixture was positively associated with odds of gestational hypertension [75th vs. 50th percentile: OR = 1.14 (95% credible interval:1.03, 1.25), BKMR] and mean DBP [T2 = 0.17 mmHg (−0.06, 0.40); T3 = 0.22 mmHg (−0.03, 0.48), BKMR]. Conclusions: These findings suggest that exposure to certain PFAS may increase the odds of gestational hypertension during pregnancy, with potential implications for subsequent maternal and child health outcomes.http://www.sciencedirect.com/science/article/pii/S0160412022002628PFASHypertensive disorders of pregnancyPreeclampsiaGestational hypertensionBlood pressure |
| spellingShingle | Emma V. Preston Marie-France Hivert Abby F. Fleisch Antonia M. Calafat Sharon K. Sagiv Wei Perng Sheryl L. Rifas-Shiman Jorge E. Chavarro Emily Oken Ami R. Zota Tamarra James-Todd Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort Environment International PFAS Hypertensive disorders of pregnancy Preeclampsia Gestational hypertension Blood pressure |
| title | Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort |
| title_full | Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort |
| title_fullStr | Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort |
| title_full_unstemmed | Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort |
| title_short | Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort |
| title_sort | early pregnancy plasma per and polyfluoroalkyl substance pfas concentrations and hypertensive disorders of pregnancy in the project viva cohort |
| topic | PFAS Hypertensive disorders of pregnancy Preeclampsia Gestational hypertension Blood pressure |
| url | http://www.sciencedirect.com/science/article/pii/S0160412022002628 |
| work_keys_str_mv | AT emmavpreston earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT mariefrancehivert earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT abbyffleisch earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT antoniamcalafat earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT sharonksagiv earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT weiperng earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT sheryllrifasshiman earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT jorgeechavarro earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT emilyoken earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT amirzota earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort AT tamarrajamestodd earlypregnancyplasmaperandpolyfluoroalkylsubstancepfasconcentrationsandhypertensivedisordersofpregnancyintheprojectvivacohort |